Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dario Strbenac

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Oncotarget|June 19, 2015
Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signalingAnja Heinemann, Carleen Cullinane, Ricardo De Paoli-Iseppi, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 20, 2023
Comparing Genomic Landscapes of Oral and Cutaneous Squamous Cell Carcinoma of the Head and Neck: Quest for Novel Diagnostic MarkersRuta Gupta, Dario Strbenac, Laveniya Satgunaseelan, et al.
Oncotarget|August 26, 2015
Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genesJessamy C Tiffen, Dilini Gunatilake, Stuart J Gallagher, et al.
NPJ Parkinson'S Disease|June 20, 2025
Dopamine and cortical neurons with different Parkinsonian mutations show variation in lysosomal and mitochondrial dysfunctionJessica Chedid, Yan Li, Adahir Labrador-Garrido, et al.
Cancers|December 5, 2019
Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic MelanomaRussell J Diefenbach, Jenny H Lee, Dario Strbenac, et al.
Diabetes Research and Clinical Practice|February 23, 2026
Chronic complication risk and benefits of fenofibrate in type 2 diabetes by a PPARα polymorphism (rs6008845, C/T): a FIELD trial substudyAndrzej S Januszewski, Michael L H Huang, Abubakar Mangani, et al.
Nature Communications|April 22, 2020
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibitionJenny H Lee, Elena Shklovskaya, Su Yin Lim, et al.
Molecular Cancer Therapeutics|July 7, 2025
Integration of whole genome sequencing analysis with unique patient-derived models reveals clinically relevant drug targets in TFCP2 fusion-defined rhabdomyosarcomaPatrick Bergsma, Sean Porazinski, Aji Istadi, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Oncotarget|June 19, 2015
Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signalingAnja Heinemann, Carleen Cullinane, Ricardo De Paoli-Iseppi, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 20, 2023
Comparing Genomic Landscapes of Oral and Cutaneous Squamous Cell Carcinoma of the Head and Neck: Quest for Novel Diagnostic MarkersRuta Gupta, Dario Strbenac, Laveniya Satgunaseelan, et al.
Oncotarget|August 26, 2015
Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genesJessamy C Tiffen, Dilini Gunatilake, Stuart J Gallagher, et al.
NPJ Parkinson'S Disease|June 20, 2025
Dopamine and cortical neurons with different Parkinsonian mutations show variation in lysosomal and mitochondrial dysfunctionJessica Chedid, Yan Li, Adahir Labrador-Garrido, et al.
Cancers|December 5, 2019
Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic MelanomaRussell J Diefenbach, Jenny H Lee, Dario Strbenac, et al.
Diabetes Research and Clinical Practice|February 23, 2026
Chronic complication risk and benefits of fenofibrate in type 2 diabetes by a PPARα polymorphism (rs6008845, C/T): a FIELD trial substudyAndrzej S Januszewski, Michael L H Huang, Abubakar Mangani, et al.
Nature Communications|April 22, 2020
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibitionJenny H Lee, Elena Shklovskaya, Su Yin Lim, et al.
Molecular Cancer Therapeutics|July 7, 2025
Integration of whole genome sequencing analysis with unique patient-derived models reveals clinically relevant drug targets in TFCP2 fusion-defined rhabdomyosarcomaPatrick Bergsma, Sean Porazinski, Aji Istadi, et al.
Pageof 4